Cargando…
Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia
Autores principales: | Jatho, Aline, Zieseniss, Anke, Brechtel-Curth, Katja, Yamamoto, Atsushi, Coleman, Mathew L., Vergel Leon, Ana M., Biggs, Daniel, Davies, Ben, Pugh, Chris W., Ratcliffe, Peter J., Katschinski, Dörthe M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048377/ https://www.ncbi.nlm.nih.gov/pubmed/33626887 http://dx.doi.org/10.1161/CIRCRESAHA.120.318216 |
Ejemplares similares
-
The HIFα-Stabilizing Drug Roxadustat Increases the Number of Renal Epo-Producing Sca-1(+) Cells
por: Jatho, Aline, et al.
Publicado: (2022) -
Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
por: Chan, Mun Chiang, et al.
Publicado: (2016) -
Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
por: Chowdhury, Rasheduzzaman, et al.
Publicado: (2016) -
Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials
por: Yeh, Tzu-Lan, et al.
Publicado: (2017) -
Lack of activity of recombinant HIF prolyl hydroxylases (PHDs) on reported non-HIF substrates
por: Cockman, Matthew E, et al.
Publicado: (2019)